| 7.7918 0.032 (0.41%) | 09-16 14:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.64 | 1-year : | 10.48 |
| Resists | First : | 8.26 | Second : | 8.97 |
| Pivot price | 8.18  |
|||
| Supports | First : | 7.09 | Second : | 5.9 |
| MAs | MA(5) : | 7.85 |
MA(20) : | 8.22 |
| MA(100) : | 8.08 |
MA(250) : | 8.74 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 10 |
D(3) : | 7.6 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 13.02 | Low : | 6.13 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRMD ] has closed above bottom band by 16.8%. Bollinger Bands are 10.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.92 - 7.97 | 7.97 - 8 |
| Low: | 7.58 - 7.64 | 7.64 - 7.69 |
| Close: | 7.67 - 7.76 | 7.76 - 7.84 |
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Tue, 08 Sep 2026
CorMedix Inc (NASDAQ:CRMD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Mon, 07 Sep 2026
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet - Yahoo Finance
Mon, 07 Sep 2026
Bank of New York Mellon Corp Takes Position in CorMedix Inc $CRMD - MarketBeat
Tue, 01 Sep 2026
BlackRock Inc. Acquires Shares of 6,324,111 CorMedix Inc $CRMD - MarketBeat
Tue, 01 Sep 2026
CorMedix will meet investors in Boston for a Wells Fargo chat - Stock Titan
Tue, 01 Sep 2026
CorMedix (CRMD) COO holds 270K shares after cost-covering share withholding - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 58 (%) |
| Shares Short | 17,150 (K) |
| Shares Short P.Month | 15,350 (K) |
| EPS | 2.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.92 |
| Profit Margin | 40.4 % |
| Operating Margin | 42 % |
| Return on Assets (ttm) | 24.5 % |
| Return on Equity (ttm) | 54.9 % |
| Qtrly Rev. Growth | 156.5 % |
| Gross Profit (p.s.) | 5.35 |
| Sales Per Share | 5.93 |
| EBITDA (p.s.) | 3.36 |
| Qtrly Earnings Growth | 6.6 % |
| Operating Cash Flow | 254 (M) |
| Levered Free Cash Flow | 178 (M) |
| PE Ratio | 3.59 |
| PEG Ratio | 0 |
| Price to Book value | 1.32 |
| Price to Sales | 1.32 |
| Price to Cash Flow | 2.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|